# US 2026/0092084 A1 · Peptide and assembly or composition containing said peptide > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0092084 A1 - Document ID: US20260092084A1 - Status: Published application - Kind: A1 - Application number: 18/876,803 - Filed: 2023-06-23 - Published: 2026-04-02 - Earliest claimed: 2022-06-29 - Assignees: Mescue-Janusys Inc. - Applicants: Mescue-Janusys Inc. - Inventors: Mitsunori HARADA; Chuya YOSHIDA - Web page: https://patentgrep.com/patent/US20260092084A1 ## CPC - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - C07K 7/06: having 5 to 11 amino acids - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) - C07K 2319/00: Fusion polypeptide - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A peptide or a derivative thereof or a salt thereof, including a hydrophobic region, and a hydrophilic region positioned on at least one end side of the hydrophobic region and having hydrophobicity lower than that of the hydrophobic region, including, at one end, a first target binding site capable of binding to a first target, and including, at the other end, a second target binding site capable of binding to a second target. The peptide is applicable to an active targeting DDS. ## Claims ### Claim 1 A peptide or a derivative thereof, or a salt thereof, comprising a hydrophobic region, and a hydrophilic region positioned on at least one end side of the hydrophobic region and having hydrophobicity lower than that of the hydrophobic region, comprising, at one end selected from an N-terminus and a C-terminus thereof, a first target binding site capable of binding to a first target, and comprising, at the other end, a second target binding site capable of binding to a second target. ### Claim 2 (depends on 1) The peptide or the derivative thereof, or the salt thereof according to claim 1, wherein the first target and the second target are different from each other. ### Claim 3 (depends on 1) The peptide or the derivative thereof, or the salt thereof according to claim 1, wherein the number of amino acid residues for forming the peptide or the derivative thereof, or the salt thereof is from 10 to 40. ### Claim 4 (depends on 1) The peptide or the derivative thereof, or the salt thereof according to claim 1, wherein the peptide or the derivative thereof, or the salt thereof comprises the hydrophilic regions on both end sides of the hydrophobic region. ### Claim 5 (depends on 4) The peptide or the derivative thereof, or the salt thereof according to claim 4, wherein the number of amino acid residues for forming the hydrophobic region is from 2 to 15, and 60% or more of the amino acid residues are selected from a non-polar amino acid residue and a tyrosine residue. ### Claim 6 (depends on 4) The peptide or the derivative thereof, or the salt thereof according to claim 4, wherein the numbers of amino acid residues for forming the two hydrophilic regions are each independently from 3 to 24. ### Claim 7 (depends on 1) The peptide or the derivative thereof, or the salt thereof according to claim 1, wherein the peptide or the derivative thereof, or the salt thereof comprises the hydrophilic region on only one end side of the hydrophobic region. ### Claim 8 (depends on 1) The peptide or the derivative thereof, or the salt thereof according to claim 1, wherein at least one of the first target binding site or the second target binding site has biological activity. ### Claim 9 (depends on 1) A peptide assembly, comprising the peptide or the derivative thereof, or the salt thereof of claim 1. ### Claim 10 (depends on 9) The peptide assembly according to claim 9, further comprising a drug. ### Claim 11 (depends on 9) The peptide assembly according to claim 9, wherein the peptide assembly satisfies at least one of the following item (i) or (ii): (i) binding affinity of the peptide assembly to the first target per the peptide or the derivative thereof, or the salt thereof is equal to or more than binding affinity of a non-self-associating peptide including the first target binding site to the first target; and (ii) binding affinity of the peptide assembly to the second target per the peptide or the derivative thereof, or the salt thereof is equal to or more than binding affinity of a non-self-associating peptide including the second target binding site to the second target. ### Claim 12 (depends on 9) A peptide composition, comprising an aqueous medium and the peptide assembly of claim 9, wherein the peptide assembly is formed through association via an intermolecular interaction including a hydrophobic interaction between the hydrophobic regions of the peptides. ### Claim 13 (depends on 12) The peptide composition according to claim 12, wherein the peptide assembly further comprises a drug.